| Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis X Zhang, JW Hay, X Niu CNS drugs 29, 71-81, 2015 | 44* | 2015 |
| Does enrollment in high‐deductible health plans encourage price shopping? X Zhang, A Haviland, A Mehrotra, P Huckfeldt, Z Wagner, N Sood Health Services Research 53, 2718-2734, 2018 | 35 | 2018 |
| Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world … E Nadler, B Arondekar, KM Aguilar, J Zhou, J Chang, X Zhang, V Pawar Journal of Cancer Research and Clinical Oncology 147, 671-690, 2021 | 32 | 2021 |
| Cost per response analysis of strategies for chronic immune thrombocytopenia K Fust, A Parthan, X Li, A Sharma, X Zhang, M Campioni, J Lin, X Wang, ... Am J Manag Care 24 (8), SP294-SP302, 2018 | 23* | 2018 |
| Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the … J Lester, C Escriu, S Khan, E Hudson, T Mansy, A Conn, S Chan, ... BMC cancer 21 (1), 515, 2021 | 20 | 2021 |
| Cost effectiveness of blinatumomab versus inotuzumab ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States TE Delea, X Zhang, J Amdahl, D Boyko, F Dirnberger, M Campioni, ... Pharmacoeconomics 37, 1177-1193, 2019 | 20 | 2019 |
| Financial burden of healthcare utilization in consumer-directed health plans X Zhang, E Trish, N Sood Am J Manag Care 24 (4), e115-e121, 2018 | 19 | 2018 |
| Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey A Pigneux, P Montesinos, Z Cong, X Zhang, AK Pownell, H Wieffer, ... BMC cancer 18, 1-8, 2018 | 18 | 2018 |
| Cost of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a population-based retrospective cohort study of administrative claims data for … J Lin, X Zhang, X Li, D Chandler, I Altomare, JS Wasser, K Cetin Clinical Therapeutics 39 (3), 603-609. e1, 2017 | 17 | 2017 |
| 阿法骨化醇治疗骨质疏松的疗效——基于骨密度, 生化指标和骨折率的 Meta 分析 李洪超， 张心科， 金雪晶， 初云波， 符一男， 马爱霞 中国药物经济学 6 (3), 49-78, 2011 | 17 | 2011 |
| 氨氯地平和硝苯地平治疗原发性高血压有效性和安全性的 Meta 分析 张心科， 李洪超， 马爱霞 中国药物经济学, 12-29, 2010 | 10 | 2010 |
| Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer X Zhang, RW DeClue, L Herms, M Yang, V Pawar, ET Masters, M Ruisi, ... Immunotherapy 13 (18), 1521-1533, 2021 | 9 | 2021 |
| Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States X Zhang, DC Beachler, E Masters, F Liu, M Yang, J Dinh, A Jamal-Allial, ... Journal of Managed Care & Specialty Pharmacy 28 (2), 255-265, 2022 | 8 | 2022 |
| Interpreting within-patient changes on the EORTC QLQ-C30 and EORTC QLQ-LC13 CD Coon, M Schlichting, X Zhang The Patient-Patient-Centered Outcomes Research 15 (6), 691-702, 2022 | 7 | 2022 |
| Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United … X Zhang, X Song, L Lopez-Gonzalez, K Jariwala-Parikh, Z Cong Expert Review of Pharmacoeconomics & Outcomes Research 18 (5), 573-580, 2018 | 7 | 2018 |
| 阿法骨化醇与骨化三醇预防骨质疏松骨折药物经济学评价 马爱霞， 李洪超， 金雪晶， 张心科， 初云波， 符一男 中国医药指南 9 (32), 371-377, 2011 | 6 | 2011 |
| Economic burden of veno-occlusive disease in patients with B-cell acute lymphoblastic leukemia in the United States X Zhang, X Song, L Lopez-Gonzalez, K Jariwala-Parikh, V Romanov, ... Clinical Therapeutics 40 (10), 1711-1719. e1, 2018 | 5* | 2018 |
| Development of a conceptual model of the patient experience in small cell lung cancer: a qualitative interview study DE Altman, X Zhang, AC Fu, AR Rams, JA Baldasaro, SA Ahmad, ... Oncology and Therapy 11 (2), 231-244, 2023 | 3 | 2023 |
| Modeling challenges in cost-effectiveness analysis of first-line immuno-oncology therapies in non-small cell lung cancer: a systematic literature review T Kongnakorn, G Sarri, A Freitag, K Marczell, P Kazmierska, E Masters, ... PharmacoEconomics, 1-19, 2022 | 3 | 2022 |
| Economic burden of hematopoietic stem cell transplantation (HSCT) in patients with acute lymphoblastic leukemia (ALL) in the US X Zhang, X Song, L Lopez-Gonzalez, K Jariwala-Parikh, Z Cong Blood 130, 3376, 2017 | 2 | 2017 |
Ze CongSenior Director HEOR at GRAIL Inc在 grailbio.com 的电子邮件经过验证
